<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20241027181029&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20241027181029&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 27 Oct 2024 22:10:30 +0000</lastbuilddate>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072571. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39462278</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072571>10.1161/CIRCULATIONAHA.124.072571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462278</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Saraschandra Vallabhajosyula</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>End-Organ Injury and Failure: The True DanGer in Cardiogenic Shock</dc:title>
<dc:identifier>pmid:39462278</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072571</dc:identifier>
</item>
<item>
<title>Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock - a Secondary Analysis of the DanGer Shock Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462276/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 27. doi: 10.1161/CIRCULATIONAHA.124.072370. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the Danish-German Cardiogenic Shock (DanGer Shock) trial, use of a microaxial flow pump (mAFP) in patients with ST-segment elevation myocardial infarction (STEMI)-related CS led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this international, randomized, open label, multicenter trial, 355 adult patients with STEMI-CS were randomized to mAFP (N=179) or standard care alone (N=176). AKI was defined according to Risk, Injury, and Failure, sustained Loss and End-stage kidney disease (RIFLE) criteria and assessed using logistic regression models. Use of RRT was assessed accounting for the competing risk of death using Fine-Gray subdistribution hazard models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AKI (RIFLE≥1) was recorded in 110 patients (61%) in mAFP group and 79 (45%) in control group (p&lt;0.01); RRT was used in 75 (42%) and 47 (27%) patients, respectively (p&lt;0.01). About 2/3 of the RRTs were initiated within the first 24h from admission (n=48 (64%) in mAFP group, n=31 (66%) in control group). Occurrence of AKI and RRT were associated with higher 180-day mortality in both study arms. At 180 days, all patients alive were free of RRT. mAFP use was associated with higher rates of RRT, even when accounting for competing risk of death (subdistribution hazard: 1.67 [1.18-2.35]). This association was largely consistent among prespecified subgroups. Allocation to mAFP was associated with lower 180-day mortality irrespective of AKI or RRT (p=0.8 for interaction). Relevant predictors of AKI in both groups comprised reduced left ventricular ejection fraction, baseline kidney function, shock severity, bleeding events, and positive fluid balance. In addition, predictors of AKI specific to mAFP were suction events, higher pump speed, and longer duration of support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Shock severity, allocation to mAFP, and device-related complications were associated with an increased risk of AKI. AKI was generally associated with higher mortality, but the allocation to mAFP consistently led to lower mortality rates at 180 days irrespective of the occurrence of AKI with or without RRT initiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462276/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39462276</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072370>10.1161/CIRCULATIONAHA.124.072370</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462276</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Elric Zweck</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Rasmus P Beske</dc:creator>
<dc:creator>Lisette O Jensen</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Norman Mangner</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Vasileios Panoulas</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Anders Junker</dc:creator>
<dc:creator>Henrik Schmidt</dc:creator>
<dc:creator>Christian J Terkelsen</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Ralf Westenfeld</dc:creator>
<dc:creator>Jacob E Møller</dc:creator>
<dc:creator>DanGer Shock Investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock - a Secondary Analysis of the DanGer Shock Trial</dc:title>
<dc:identifier>pmid:39462276</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072370</dc:identifier>
</item>
<item>
<title>Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 27. doi: 10.1001/jamacardio.2024.4197. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Mechanical circulatory support with a microaxial flow pump (MAFP) has been shown to improve survival in ST-elevation myocardial infarction-induced cardiogenic shock (STEMI-CS). Understanding the impact on hemodynamic stability over time is crucial for optimizing patient treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine if an MAFP reduces the need for pharmacological circulatory support without compromising hemodynamics compared with standard care in STEMI-CS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a substudy of the Danish-German (DanGer) Shock trial, an international, multicenter, open-label randomized clinical trial. Patients from 14 heart centers across Denmark, Germany, and the UK were enrolled. Inclusion criteria for the trial were STEMI and systolic blood pressure less than 100 mm Hg or ongoing vasopressor treatment, left ventricular ejection fraction less than 45%, and arterial lactate level greater than 2.5 mmol/L. Of the enrolled patients, after exclusions from death in the catheterization laboratory or immediately on intensive care unit (ICU) admission, the remaining patients had serial recordings of hemodynamics, arterial lactate, and use of vasoactive drugs. Patients who were in comas after cardiac arrest and patients with mechanical complications or right ventricular failure were excluded. Data were analyzed from May to September 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: MAFP and standard of care or standard of care alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Hemodynamic status in terms of heart rate and blood pressure, metabolic status in terms of arterial lactate concentration, and vasoactive-inotropic score (VIS). The clinical events during the first 72 hours were as follows: death from all causes, escalation of mechanical circulatory support, and discharge alive from the ICU.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: From 355 enrolled patients, 324 (mean [IQR] age, 68 [58-75] years; 259 male [80%]) underwent ICU treatment (169 [52%] in the MAFP group, 155 [48%] in the standard-care group). Baseline characteristics were balanced. There was no difference in heart rate between groups, and mean arterial pressure was above the treatment target of 65 mm Hg in both groups but was achieved with a lower VIS in the MAFP group. No difference in arterial lactate level was found between groups at randomization, but on arrival to the ICU, the MAFP group had significantly lower arterial lactate levels compared with the standard-care group (mean difference, 1.3 mmol/L; 95% CI, 0.7-1.9 mmol/L), a difference that persisted throughout the first 24 hours of observation. The MAFP group achieved lactate normalization (&lt;2 mmol/L) 12 hours (95% CI, 5-18 hours) before the standard-care group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Use of a MAFP reduces the use of vasopressors and inotropic medication while maintaining hemodynamic stability and achieving faster normalization of lactate level in patients with STEMI-CS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01633502.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39462240</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4197>10.1001/jamacardio.2024.4197</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462240</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Nanna Louise Junker Udesen</dc:creator>
<dc:creator>Rasmus Paulin Beske</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Lisette Okkels Jensen</dc:creator>
<dc:creator>Hans Eiskjær</dc:creator>
<dc:creator>Norman Mangner</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:creator>P Christian Schulze</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Peter Nordbeck</dc:creator>
<dc:creator>Peter Clemmensen</dc:creator>
<dc:creator>Vasileios Panoulas</dc:creator>
<dc:creator>Sebastian Zimmer</dc:creator>
<dc:creator>Andreas Schäfer</dc:creator>
<dc:creator>Nikos Werner</dc:creator>
<dc:creator>Martin Frydland</dc:creator>
<dc:creator>Lene Holmvang</dc:creator>
<dc:creator>Jesper Kjærgaard</dc:creator>
<dc:creator>Thomas Engstøm</dc:creator>
<dc:creator>Henrik Schmidt</dc:creator>
<dc:creator>Anders Junker</dc:creator>
<dc:creator>Christian Juhl Terkelsen</dc:creator>
<dc:creator>Steffen Christensen</dc:creator>
<dc:creator>Axel Linke</dc:creator>
<dc:creator>Jacob Eifer Møller</dc:creator>
<dc:creator>DanGer Shock Investigators</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Microaxial Flow Pump Hemodynamic and Metabolic Effects in Infarct-Related Cardiogenic Shock: A Substudy of the DanGer Shock Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39462240</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4197</dc:identifier>
</item>
<item>
<title>Evidence for Mechanical Circulatory Support in Cardiogenic Shock</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39462239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 27. doi: 10.1001/jamacardio.2024.4225. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39462239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39462239</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4225>10.1001/jamacardio.2024.4225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39462239</guid>
<pubDate>Sun, 27 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jason E Bloom</dc:creator>
<dc:creator>Kais Hyasat</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:date>2024-10-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Evidence for Mechanical Circulatory Support in Cardiogenic Shock</dc:title>
<dc:identifier>pmid:39462239</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4225</dc:identifier>
</item>
<item>
<title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39461336/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 25:S0092-8674(24)01218-2. doi: 10.1016/j.cell.2024.10.036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39461336/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39461336</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.036>10.1016/j.cell.2024.10.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39461336</guid>
<pubDate>Sat, 26 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Kaili Fu</dc:creator>
<dc:creator>Alvin Ho Kwan Cheung</dc:creator>
<dc:creator>Chi Chun Wong</dc:creator>
<dc:creator>Weixin Liu</dc:creator>
<dc:creator>Yunfei Zhou</dc:creator>
<dc:creator>Feixue Wang</dc:creator>
<dc:creator>Pingmei Huang</dc:creator>
<dc:creator>Kai Yuan</dc:creator>
<dc:creator>Olabisi Oluwabukola Coker</dc:creator>
<dc:creator>Yasi Pan</dc:creator>
<dc:creator>Danyu Chen</dc:creator>
<dc:creator>Nga Man Lam</dc:creator>
<dc:creator>Mengxue Gao</dc:creator>
<dc:creator>Xiang Zhang</dc:creator>
<dc:creator>He Huang</dc:creator>
<dc:creator>Ka Fai To</dc:creator>
<dc:creator>Joseph Jao Yiu Sung</dc:creator>
<dc:creator>Jun Yu</dc:creator>
<dc:date>2024-10-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice</dc:title>
<dc:identifier>pmid:39461336</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.036</dc:identifier>
</item>
<item>
<title>Environmental sustainability in cardiovascular practice: current challenges and future directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39455886/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular disease is the leading cause of morbidity and mortality worldwide, with a substantial amount of health-care resources targeted towards its diagnosis and management. Environmental sustainability in cardiovascular care can have an important role in reducing greenhouse gas emissions and pollution and could be beneficial for improving health metrics and societal well-being and minimizing the cost of health care. In this Review, we discuss the motivations and frameworks for sustainable...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 25. doi: 10.1038/s41569-024-01077-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular disease is the leading cause of morbidity and mortality worldwide, with a substantial amount of health-care resources targeted towards its diagnosis and management. Environmental sustainability in cardiovascular care can have an important role in reducing greenhouse gas emissions and pollution and could be beneficial for improving health metrics and societal well-being and minimizing the cost of health care. In this Review, we discuss the motivations and frameworks for sustainable cardiovascular care with an emphasis on the reduction of the climate-related and environmental effects of cardiovascular care. We also provide an overview of greenhouse gas emissions related to the provision of health care, including their measurement and quantification, carbon accounting, carbon disclosures and climate effects. The principles of life-cycle assessment, waste prevention and circular economics in health care are discussed, and the emissions associated with various sectors of cardiovascular care as well as the rationale for prevention as a powerful approach to reduce these emissions are presented. Finally, we highlight the challenges in environmental sustainability and future directions as applicable to cardiovascular practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39455886/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39455886</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01077-z>10.1038/s41569-024-01077-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39455886</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Scott McAlister</dc:creator>
<dc:creator>Jason Jay</dc:creator>
<dc:creator>Richard D Pham</dc:creator>
<dc:creator>Robert D Brook</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Mark J Nieuwenhuijsen</dc:creator>
<dc:creator>Philip Landrigan</dc:creator>
<dc:creator>Allegra Wiesler</dc:creator>
<dc:creator>Christina Vernon Sanborn</dc:creator>
<dc:creator>Justin R Carron</dc:creator>
<dc:creator>Kara Hammond Brooks</dc:creator>
<dc:creator>Aruni Bhatnagar</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Environmental sustainability in cardiovascular practice: current challenges and future directions</dc:title>
<dc:identifier>pmid:39455886</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01077-z</dc:identifier>
</item>
<item>
<title>Method of moments framework for differential expression analysis of single-cell RNA sequencing data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39454576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>Differential expression analysis of single-cell RNA sequencing (scRNA-seq) data is central for characterizing how experimental factors affect the distribution of gene expression. However, distinguishing between biological and technical sources of cell-cell variability and assessing the statistical significance of quantitative comparisons between cell groups remain challenging. We introduce Memento, a tool for robust and efficient differential analysis of mean expression, variability, and gene...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 16:S0092-8674(24)01144-9. doi: 10.1016/j.cell.2024.09.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Differential expression analysis of single-cell RNA sequencing (scRNA-seq) data is central for characterizing how experimental factors affect the distribution of gene expression. However, distinguishing between biological and technical sources of cell-cell variability and assessing the statistical significance of quantitative comparisons between cell groups remain challenging. We introduce Memento, a tool for robust and efficient differential analysis of mean expression, variability, and gene correlation from scRNA-seq data, scalable to millions of cells and thousands of samples. We applied Memento to 70,000 tracheal epithelial cells to identify interferon-responsive genes, 160,000 CRISPR-Cas9 perturbed T cells to reconstruct gene-regulatory networks, 1.2 million peripheral blood mononuclear cells (PBMCs) to map cell-type-specific quantitative trait loci (QTLs), and the 50-million-cell CELLxGENE Discover corpus to compare arbitrary cell groups. In all cases, Memento identified more significant and reproducible differences in mean expression compared with existing methods. It also identified differences in variability and gene correlation that suggest distinct transcriptional regulation mechanisms imparted by perturbations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39454576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39454576</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.044>10.1016/j.cell.2024.09.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39454576</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Min Cheol Kim</dc:creator>
<dc:creator>Rachel Gate</dc:creator>
<dc:creator>David S Lee</dc:creator>
<dc:creator>Andrew Tolopko</dc:creator>
<dc:creator>Andrew Lu</dc:creator>
<dc:creator>Erin Gordon</dc:creator>
<dc:creator>Eric Shifrut</dc:creator>
<dc:creator>Pablo E Garcia-Nieto</dc:creator>
<dc:creator>Alexander Marson</dc:creator>
<dc:creator>Vasilis Ntranos</dc:creator>
<dc:creator>Chun Jimmie Ye</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Method of moments framework for differential expression analysis of single-cell RNA sequencing data</dc:title>
<dc:identifier>pmid:39454576</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.044</dc:identifier>
</item>
<item>
<title>Mechanisms of memory-supporting neuronal dynamics in hippocampal area CA3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39454575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>Hippocampal CA3 is central to memory formation and retrieval. Although various network mechanisms have been proposed, direct evidence is lacking. Using intracellular V(m) recordings and optogenetic manipulations in behaving mice, we found that CA3 place-field activity is produced by a symmetric form of behavioral timescale synaptic plasticity (BTSP) at recurrent synapses among CA3 pyramidal neurons but not at synapses from the dentate gyrus (DG). Additional manipulations revealed that excitatory...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 17:S0092-8674(24)01141-3. doi: 10.1016/j.cell.2024.09.041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hippocampal CA3 is central to memory formation and retrieval. Although various network mechanisms have been proposed, direct evidence is lacking. Using intracellular V<sub>m</sub> recordings and optogenetic manipulations in behaving mice, we found that CA3 place-field activity is produced by a symmetric form of behavioral timescale synaptic plasticity (BTSP) at recurrent synapses among CA3 pyramidal neurons but not at synapses from the dentate gyrus (DG). Additional manipulations revealed that excitatory input from the entorhinal cortex (EC) but not the DG was required to update place cell activity based on the animal's movement. These data were captured by a computational model that used BTSP and an external updating input to produce attractor dynamics under online learning conditions. Theoretical analyses further highlight the superior memory storage capacity of such networks, especially when dealing with correlated input patterns. This evidence elucidates the cellular and circuit mechanisms of learning and memory formation in the hippocampus.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39454575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39454575</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.041>10.1016/j.cell.2024.09.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39454575</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yiding Li</dc:creator>
<dc:creator>John J Briguglio</dc:creator>
<dc:creator>Sandro Romani</dc:creator>
<dc:creator>Jeffrey C Magee</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Mechanisms of memory-supporting neuronal dynamics in hippocampal area CA3</dc:title>
<dc:identifier>pmid:39454575</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.041</dc:identifier>
</item>
<item>
<title>A multimodal zebrafish developmental atlas reveals the state-transition dynamics of late-vertebrate pluripotent axial progenitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39454574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>Elucidating organismal developmental processes requires a comprehensive understanding of cellular lineages in the spatial, temporal, and molecular domains. In this study, we introduce Zebrahub, a dynamic atlas of zebrafish embryonic development that integrates single-cell sequencing time course data with lineage reconstructions facilitated by light-sheet microscopy. This atlas offers high-resolution and in-depth molecular insights into zebrafish development, achieved through the sequencing of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 23:S0092-8674(24)01147-4. doi: 10.1016/j.cell.2024.09.047. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Elucidating organismal developmental processes requires a comprehensive understanding of cellular lineages in the spatial, temporal, and molecular domains. In this study, we introduce Zebrahub, a dynamic atlas of zebrafish embryonic development that integrates single-cell sequencing time course data with lineage reconstructions facilitated by light-sheet microscopy. This atlas offers high-resolution and in-depth molecular insights into zebrafish development, achieved through the sequencing of individual embryos across ten developmental stages, complemented by reconstructions of cellular trajectories. Zebrahub also incorporates an interactive tool to navigate the complex cellular flows and lineages derived from light-sheet microscopy data, enabling in silico fate-mapping experiments. To demonstrate the versatility of our multimodal resource, we utilize Zebrahub to provide fresh insights into the pluripotency of neuro-mesodermal progenitors (NMPs) and the origins of a joint kidney-hemangioblast progenitor population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39454574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39454574</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.047>10.1016/j.cell.2024.09.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39454574</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Merlin Lange</dc:creator>
<dc:creator>Alejandro Granados</dc:creator>
<dc:creator>Shruthi VijayKumar</dc:creator>
<dc:creator>Jordão Bragantini</dc:creator>
<dc:creator>Sarah Ancheta</dc:creator>
<dc:creator>Yang-Joon Kim</dc:creator>
<dc:creator>Sreejith Santhosh</dc:creator>
<dc:creator>Michael Borja</dc:creator>
<dc:creator>Hirofumi Kobayashi</dc:creator>
<dc:creator>Erin McGeever</dc:creator>
<dc:creator>Ahmet Can Solak</dc:creator>
<dc:creator>Bin Yang</dc:creator>
<dc:creator>Xiang Zhao</dc:creator>
<dc:creator>Yang Liu</dc:creator>
<dc:creator>Angela M Detweiler</dc:creator>
<dc:creator>Sheryl Paul</dc:creator>
<dc:creator>Ilan Theodoro</dc:creator>
<dc:creator>Honey Mekonen</dc:creator>
<dc:creator>Chris Charlton</dc:creator>
<dc:creator>Tiger Lao</dc:creator>
<dc:creator>Rachel Banks</dc:creator>
<dc:creator>Sheng Xiao</dc:creator>
<dc:creator>Adrian Jacobo</dc:creator>
<dc:creator>Keir Balla</dc:creator>
<dc:creator>Kyle Awayan</dc:creator>
<dc:creator>Samuel D'Souza</dc:creator>
<dc:creator>Robert Haase</dc:creator>
<dc:creator>Alexandre Dizeux</dc:creator>
<dc:creator>Olivier Pourquie</dc:creator>
<dc:creator>Rafael Gómez-Sjöberg</dc:creator>
<dc:creator>Greg Huber</dc:creator>
<dc:creator>Mattia Serra</dc:creator>
<dc:creator>Norma Neff</dc:creator>
<dc:creator>Angela Oliveira Pisco</dc:creator>
<dc:creator>Loïc A Royer</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A multimodal zebrafish developmental atlas reveals the state-transition dynamics of late-vertebrate pluripotent axial progenitors</dc:title>
<dc:identifier>pmid:39454574</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.047</dc:identifier>
</item>
<item>
<title>Clade I mpox virus genomic diversity in the Democratic Republic of the Congo, 2018-2024: Predominance of zoonotic transmission</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39454573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>Recent reports raise concerns on the changing epidemiology of mpox in the Democratic Republic of the Congo (DRC). High-quality genomes were generated for 337 patients from 14/26 provinces to document whether the increase in number of cases is due to zoonotic spillover events or viral evolution, with enrichment of APOBEC3 mutations linked to human adaptation. Our study highlights two patterns of transmission contributing to the source of human cases. All new sequences from the eastern South Kivu...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 24:S0092-8674(24)01199-1. doi: 10.1016/j.cell.2024.10.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent reports raise concerns on the changing epidemiology of mpox in the Democratic Republic of the Congo (DRC). High-quality genomes were generated for 337 patients from 14/26 provinces to document whether the increase in number of cases is due to zoonotic spillover events or viral evolution, with enrichment of APOBEC3 mutations linked to human adaptation. Our study highlights two patterns of transmission contributing to the source of human cases. All new sequences from the eastern South Kivu province (n = 17; 4.8%) corresponded to the recently described clade Ib, associated with sexual contact and sustained human-to-human transmission. By contrast, all other genomes are clade Ia, which exhibits high genetic diversity with low numbers of APOBEC3 mutations compared with clade Ib, suggesting multiple zoonotic introductions. The presence of multiple clade I variants in urban areas highlights the need for coordinated international response efforts and more studies on the transmission and the reservoir of mpox.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39454573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39454573</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.017>10.1016/j.cell.2024.10.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39454573</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eddy Kinganda-Lusamaki</dc:creator>
<dc:creator>Adrienne Amuri-Aziza</dc:creator>
<dc:creator>Nicolas Fernandez-Nuñez</dc:creator>
<dc:creator>Jean-Claude Makangara-Cigolo</dc:creator>
<dc:creator>Catherine Pratt</dc:creator>
<dc:creator>Emmanuel Hasivirwe Vakaniaki</dc:creator>
<dc:creator>Nicole A Hoff</dc:creator>
<dc:creator>Gradi Luakanda-Ndelemo</dc:creator>
<dc:creator>Prince Akil-Bandali</dc:creator>
<dc:creator>Sabin Sabiti Nundu</dc:creator>
<dc:creator>Noella Mulopo-Mukanya</dc:creator>
<dc:creator>Michel Ngimba</dc:creator>
<dc:creator>Brigitte Modadra-Madakpa</dc:creator>
<dc:creator>Ruth Diavita</dc:creator>
<dc:creator>Princesse Paku-Tshambu</dc:creator>
<dc:creator>Elisabeth Pukuta-Simbu</dc:creator>
<dc:creator>Sydney Merritt</dc:creator>
<dc:creator>Áine O'Toole</dc:creator>
<dc:creator>Nicola Low</dc:creator>
<dc:creator>Antoine Nkuba-Ndaye</dc:creator>
<dc:creator>Hugo Kavunga-Membo</dc:creator>
<dc:creator>Robert Shongo Lushima</dc:creator>
<dc:creator>Laurens Liesenborghs</dc:creator>
<dc:creator>Tony Wawina-Bokalanga</dc:creator>
<dc:creator>Koen Vercauteren</dc:creator>
<dc:creator>Daniel Mukadi-Bamuleka</dc:creator>
<dc:creator>Lorenzo Subissi</dc:creator>
<dc:creator>Jean-Jacques Muyembe-Tamfum</dc:creator>
<dc:creator>Jason Kindrachuk</dc:creator>
<dc:creator>Ahidjo Ayouba</dc:creator>
<dc:creator>Andrew Rambaut</dc:creator>
<dc:creator>Eric Delaporte</dc:creator>
<dc:creator>Sofonias Tessema</dc:creator>
<dc:creator>Eric D'Ortenzio</dc:creator>
<dc:creator>Anne W Rimoin</dc:creator>
<dc:creator>Lisa E Hensley</dc:creator>
<dc:creator>Placide Mbala-Kingebeni</dc:creator>
<dc:creator>Martine Peeters</dc:creator>
<dc:creator>Steve Ahuka-Mundeke</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Clade I mpox virus genomic diversity in the Democratic Republic of the Congo, 2018-2024: Predominance of zoonotic transmission</dc:title>
<dc:identifier>pmid:39454573</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.017</dc:identifier>
</item>
<item>
<title>NAT10 promotes vascular remodelling via mRNA ac4C acetylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453784/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study reveals that NAT10 promotes vascular remodelling via mRNA ac4C acetylation, which may be a promising therapeutic target against vascular remodelling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae707. doi: 10.1093/eurheartj/ehae707. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Vascular smooth muscle cell (VSMC) phenotype switching is a pathological hallmark in various cardiovascular diseases. N4-acetylcytidine (ac4C) catalyzed by N-acetyltransferase 10 (NAT10) is well conserved in the enzymatic modification of ribonucleic acid (RNA). NAT10-mediated ac4C acetylation is involved in various physiological and pathological processes, including cardiac remodelling. However, the biological functions and underlying regulatory mechanisms of mRNA ac4C modifications in vascular diseases remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: By combining in-vitro and in-vivo vascular injury models, NAT10 was identified as a crucial protein involved in the promotion of post-injury neointima formation, as well as VSMC phenotype switching. The potential mechanisms of NAT10 in the vascular neointima formation were clarified by RNA sequence (RNA-seq), acetylated mRNA immunoprecipitation sequence (acRIP-seq), and RNA binding protein immunoprecipitation sequence (RIP-seq).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NAT10 and ac4C modifications were upregulated in injured human and rodent arteries. Deletion of NAT10 in VSMCs effectively reduced post-injury neointima formation and VSMC phenotype switching. Further RNA-seq, RIP-seq, and acRIP-seq revealed that NAT10, by its ac4C modification, directly interacts with genes, including integrin-β1 (ITGB1) and collagen type I alpha 2 chain (Col1a2) mRNAs. Taking ITGB1 as one example, it showed that NAT10-mediated ac4C consequently increased ITGB1 mRNA stability and its downstream focal adhesion kinase (FAK) signaling, directly influencing the proliferation of VSMCs and vascular remodelling. The regulation of NAT10 on the VSMC phenotype is of translational significance because the administration of Remodelin, a NAT10 inhibitor, effectively prevents neointima formation by suppressing VSMC proliferation and downregulating ITGB1 expression and deactivating its FAK signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study reveals that NAT10 promotes vascular remodelling via mRNA ac4C acetylation, which may be a promising therapeutic target against vascular remodelling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453784/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453784</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae707>10.1093/eurheartj/ehae707</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453784</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Cheng Yu</dc:creator>
<dc:creator>Yue Chen</dc:creator>
<dc:creator>Hao Luo</dc:creator>
<dc:creator>Weihong Lin</dc:creator>
<dc:creator>Xin Lin</dc:creator>
<dc:creator>Qiong Jiang</dc:creator>
<dc:creator>Hongjin Liu</dc:creator>
<dc:creator>Wenkun Liu</dc:creator>
<dc:creator>Jing Yang</dc:creator>
<dc:creator>Yu Huang</dc:creator>
<dc:creator>Jun Fang</dc:creator>
<dc:creator>Duofen He</dc:creator>
<dc:creator>Yu Han</dc:creator>
<dc:creator>Shuo Zheng</dc:creator>
<dc:creator>Hongmei Ren</dc:creator>
<dc:creator>Xuewei Xia</dc:creator>
<dc:creator>Junyi Yu</dc:creator>
<dc:creator>Lianglong Chen</dc:creator>
<dc:creator>Chunyu Zeng</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>NAT10 promotes vascular remodelling via mRNA ac4C acetylation</dc:title>
<dc:identifier>pmid:39453784</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae707</dc:identifier>
</item>
<item>
<title>Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Despite an overall good prognosis, low RF-CL patients have reduced risk of myocardial infarction or death when allocated to coronary CTA vs. usual care. Risk is similar in patients with very-low and moderate/high likelihood.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae742. doi: 10.1093/eurheartj/ehae742. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Whether index testing using coronary computed tomography angiography (CTA) improves outcomes in stable chest pain is debated. The risk factor weighted clinical likelihood (RF-CL) model provides likelihood estimation of obstructive coronary artery disease. This study investigated the prognostic effect of coronary CTA vs. usual care by RF-CL estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Large-scale studies randomized patients (N = 13 748) with stable chest pain to coronary CTA as part of the initial work-up in addition to or instead of usual care including functional testing. Patients were stratified according to RF-CL estimates [RF-CL: very-low (≤5%), low (>;5%-15%), and moderate/high (>;15%)]. The primary endpoint was myocardial infarction or death at 3 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The primary endpoint occurred in 313 (2.3%) patients. Event rates were similar in patients allocated to coronary CTA vs. usual care [risk difference (RD) 0.3%, hazard ratio (HR) 0.84 (95% CI 0.67-1.05)]. Overall, 33%, 44%, and 23% patients had very-low, low, and moderate/high RF-CL. Risk was similar in patients with very low and moderate/high RF-CL allocated to coronary CTA vs. usual care [very low: RD 0.3%, HR 1.27 (0.74-2.16); moderate/high: RD 0.5%, HR 0.88 (0.63-1.23)]. Conversely, patients with low RF-CL undergoing coronary CTA had lower event rates [RD 0.7%, HR 0.67 (95% CI 0.47-0.97)]. The number needed to test using coronary CTA to prevent one event within 3 years was 143.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Despite an overall good prognosis, low RF-CL patients have reduced risk of myocardial infarction or death when allocated to coronary CTA vs. usual care. Risk is similar in patients with very-low and moderate/high likelihood.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453783/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453783</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae742>10.1093/eurheartj/ehae742</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453783</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Laust Dupont Rasmussen</dc:creator>
<dc:creator>Samuel Emil Schmidt</dc:creator>
<dc:creator>Juhani Knuuti</dc:creator>
<dc:creator>Christiaan Vrints</dc:creator>
<dc:creator>Morten Bøttcher</dc:creator>
<dc:creator>Borek Foldyna</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Pamela S Douglas</dc:creator>
<dc:creator>Simon Winther</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Clinical risk prediction, coronary computed tomography angiography, and cardiovascular events in new-onset chest pain: the PROMISE and SCOT-HEART trials</dc:title>
<dc:identifier>pmid:39453783</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae742</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: the rise and OCEANIC fall of asundexian in atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae728. doi: 10.1093/eurheartj/ehae728. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453777</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae728>10.1093/eurheartj/ehae728</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453777</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Carlo Patrono</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: the rise and OCEANIC fall of asundexian in atrial fibrillation</dc:title>
<dc:identifier>pmid:39453777</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae728</dc:identifier>
</item>
<item>
<title>Adults with congenital heart disease: what every cardiologist should know about their care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>As patients with congenital heart disease (CHD) continue to enjoy longer lives, non-congenital cardiologists and other healthcare professionals are increasingly encountering them in their practice and are challenged by their specific needs. Most under- and post-graduate medical training tends to overlook this common pathology, resulting in insufficient awareness of post-repair or post-palliation residual lesions and sequelae from previous interventions. In a strive towards improving the quality...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae716. doi: 10.1093/eurheartj/ehae716. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">As patients with congenital heart disease (CHD) continue to enjoy longer lives, non-congenital cardiologists and other healthcare professionals are increasingly encountering them in their practice and are challenged by their specific needs. Most under- and post-graduate medical training tends to overlook this common pathology, resulting in insufficient awareness of post-repair or post-palliation residual lesions and sequelae from previous interventions. In a strive towards improving the quality of care for this ever-growing cardiovascular patient cohort, it is prudent to outline the areas of concern and specific management needs pertaining to adult patients with CHD and share it with non-CHD professionals. The purpose of this paper is to offer essential guidance to physicians, including cardiologists, when they encounter a patient with CHD in a non-congenital healthcare setting.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453759</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae716>10.1093/eurheartj/ehae716</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453759</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Werner Budts</dc:creator>
<dc:creator>Katja Prokšelj</dc:creator>
<dc:creator>Daniel Lovrić</dc:creator>
<dc:creator>Polona Kačar</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:creator>Margarita Brida</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adults with congenital heart disease: what every cardiologist should know about their care</dc:title>
<dc:identifier>pmid:39453759</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae716</dc:identifier>
</item>
<item>
<title>Gestational diabetes and future cardiovascular diseases: associations by sex-specific genetic data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This study demonstrated a suggestive causal relationship between genetic predisposition to gestational diabetes mellitus and the risk of coronary artery disease, which was mainly mediated by Type 2 diabetes and hypertension. These findings highlight targeting modifiable cardiometabolic risk factors may reduce the risk of coronary artery disease in women with a history of gestational diabetes mellitus.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 25:ehae706. doi: 10.1093/eurheartj/ehae706. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Observational studies have highlighted that gestational diabetes mellitus is associated with a higher risk of cardiovascular diseases, but the causality remains unclear. Herein, the causality between genetic predisposition to gestational diabetes mellitus and the risk of cardiovascular diseases was investigated using sex-specific Mendelian randomization analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Linkage disequilibrium score regression analysis and two-sample Mendelian randomization analysis were applied to infer the genetic correlation and causality, respectively. Mediation analysis was conducted using a two-step Mendelian randomization approach. Sensitivity analyses were performed to differentiate causality from pleiotropy. The genome-wide association study summary statistics for gestational diabetes mellitus were obtained from FinnGen consortium, while for cardiovascular diseases were generated based on individual-level genetic data from the UK Biobank.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Linkage disequilibrium score regression analyses revealed that gestational diabetes mellitus had a significant genetic correlation with coronary artery disease and myocardial infarction after Benjamini-Hochberg correction in ever-pregnant women. In Mendelian randomization analyses, odds ratios (95% confidence interval) for coronary artery disease and myocardial infarction were 1.09 (1.01-1.17) and 1.12 (.96-1.31) per unit increase in the log-odds of genetic predisposition to gestational diabetes mellitus in ever-pregnant women, respectively. Further, Type 2 diabetes and hypertension were identified as mediators for the causality of genetic predisposition to gestational diabetes mellitus on coronary artery disease. In sensitivity analyses, the direction of odds ratio for the association between instrumental variables with gestational diabetes mellitus-predominant effects and the risk of coronary artery disease was consistent with the primary results in ever-pregnant women, although not statistically significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This study demonstrated a suggestive causal relationship between genetic predisposition to gestational diabetes mellitus and the risk of coronary artery disease, which was mainly mediated by Type 2 diabetes and hypertension. These findings highlight targeting modifiable cardiometabolic risk factors may reduce the risk of coronary artery disease in women with a history of gestational diabetes mellitus.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453753</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae706>10.1093/eurheartj/ehae706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453753</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yeshen Zhang</dc:creator>
<dc:creator>Shijie Yu</dc:creator>
<dc:creator>Ziying Chen</dc:creator>
<dc:creator>Haobin Liu</dc:creator>
<dc:creator>Huixian Li</dc:creator>
<dc:creator>Xinyang Long</dc:creator>
<dc:creator>Fei Ye</dc:creator>
<dc:creator>Wenzhi Luo</dc:creator>
<dc:creator>Yining Dai</dc:creator>
<dc:creator>Shan Tu</dc:creator>
<dc:creator>Weikun Chen</dc:creator>
<dc:creator>Siyu Kong</dc:creator>
<dc:creator>Yu He</dc:creator>
<dc:creator>Ling Xue</dc:creator>
<dc:creator>Ning Tan</dc:creator>
<dc:creator>Huiying Liang</dc:creator>
<dc:creator>Zhihui Zhang</dc:creator>
<dc:creator>Pengcheng He</dc:creator>
<dc:creator>Chongyang Duan</dc:creator>
<dc:creator>Yuanhui Liu</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Gestational diabetes and future cardiovascular diseases: associations by sex-specific genetic data</dc:title>
<dc:identifier>pmid:39453753</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae706</dc:identifier>
</item>
<item>
<title>Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1) loss of on-treatment effect with no observed changes following discontinuation (eg, prazosin); 2) attenuation or loss of on-treatment effect with rebound clinical worsening following discontinuation (eg, nitroprusside); 3) persistence of deleterious on-treatment effect followed by clinical worsening...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08453-5. doi: 10.1016/j.jacc.2024.09.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1) loss of on-treatment effect with no observed changes following discontinuation (eg, prazosin); 2) attenuation or loss of on-treatment effect with rebound clinical worsening following discontinuation (eg, nitroprusside); 3) persistence of deleterious on-treatment effect followed by clinical worsening after discontinuation (eg, milrinone and flosequinan); and 4) persistence of favorable on-treatment effect followed by clinical worsening after discontinuation (eg, digoxin and sodium-glucose cotransporter 2 inhibitors). Persuasive evidence for persistence of efficacy has been demonstrated for the use of digoxin, diuretic agents, sodium-glucose cotransporter 2 inhibitors, and (to a limited extent) for angiotensin-converting enzyme inhibitors. Available evidence for worsening of clinical status following the withdrawal of neurohormonal antagonists largely consists of observational studies. However, their findings are difficult to interpret because of considerable confounding related to the fact that drugs were withdrawn for clinical reasons, which represented a more important contributor to the poor outcome of these patients than the withdrawal of an effective drug. Nevertheless, the totality of available evidence points to a meaningful clinical deterioration within a few weeks following the withdrawal for most drugs that have been evaluated for the treatment of heart failure. These findings suggests that that our current emphasis on the implementation of foundational drugs needs to include an equally important emphasis to avoid even short-term gaps in treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453366</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.005>10.1016/j.jacc.2024.09.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453366</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Khawaja M Talha</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction</dc:title>
<dc:identifier>pmid:39453366</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.005</dc:identifier>
</item>
<item>
<title>Genetic Variation and Ablation Outcomes: A Positive Step for Genomic Medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 2:S0735-1097(24)08388-8. doi: 10.1016/j.jacc.2024.08.057. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453365/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453365</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.057>10.1016/j.jacc.2024.08.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453365</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alan Hanley</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Variation and Ablation Outcomes: A Positive Step for Genomic Medicine</dc:title>
<dc:identifier>pmid:39453365</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.057</dc:identifier>
</item>
<item>
<title>Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years: A Case-Crossover Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 9:S0735-1097(24)08389-X. doi: 10.1016/j.jacc.2024.08.058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453364/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453364</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.058>10.1016/j.jacc.2024.08.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453364</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Lingzhi Chu</dc:creator>
<dc:creator>Rong Wang</dc:creator>
<dc:creator>Cary P Gross</dc:creator>
<dc:creator>Kai Chen</dc:creator>
<dc:creator>Xiaomei Ma</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years: A Case-Crossover Study</dc:title>
<dc:identifier>pmid:39453364</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.058</dc:identifier>
</item>
<item>
<title>Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with group 1 PH identifies a subset of patients with worse dynamic PCWP response indicative of subclinical left heart disease, with poorer functional status, quality of life, and survival. Further study in this group 1 PH subgroup is indicated to determine whether PH therapies are effective and safe, and also whether HFpEF-specific therapies can improve functional status and outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08392-X. doi: 10.1016/j.jacc.2024.08.061. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Patients with group 1 pulmonary hypertension (PH) and risk factors for heart failure with preserved ejection fraction (HFpEF) demonstrate worse response to pulmonary vasodilator therapy. The mechanisms and optimal diagnostic approach to identify such patients remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to compare exercise capacity, cardiac function, and hemodynamic responses to provocative maneuvers among patients with group 1 PH based upon pretest probability of HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pretest probability for HFpEF was determined using the validated HFpEF-ABA algorithm based on age, body mass index, and history of atrial fibrillation among group 1 PH patients recruited to the multicenter PVDOMICS (Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) study. Functional capacity, quality of life, and dynamic pulmonary capillary wedge pressure (PCWP) responses were compared between those with low (&lt;25%), intermediate (25%-74%), and high (≥75%) ABA score-based HFpEF probability.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 424 patients with group 1 PH, 54% (n = 228) had intermediate HFpEF probability and 15% (n = 64) had high HFpEF probability. Resting PCWP increased progressively with higher HFpEF probability (P &lt; 0.0001), and patients with group 1 PH and high HFpEF probability had the greatest increases in PCWP with nitric oxide, fluid challenge, and exercise (P &lt; 0.001 for all), changes that were comparable to patients with HFpEF with no pulmonary vascular disease (n = 194), but lower than those with HFpEF and combined precapillary and postcapillary PH. Left ventricular/atrial size, diastolic function, quality of life, 6-minute walk distance, and peak VO<sub>2</sub> were most abnormal in patients with group 1 PH and high HFpEF probability compared with those with low or intermediate HFpEF probability (P &lt; 0.0001 for all). Increasing HFpEF probability in group 1 PH was associated with greater risk of death (HR per decile of HFpEF probability 1.09; 95% CI: 1.05-1.13; P &lt; 0.0001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Quantifying pretest probability for HFpEF in patients with group 1 PH identifies a subset of patients with worse dynamic PCWP response indicative of subclinical left heart disease, with poorer functional status, quality of life, and survival. Further study in this group 1 PH subgroup is indicated to determine whether PH therapies are effective and safe, and also whether HFpEF-specific therapies can improve functional status and outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453363/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453363</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.061>10.1016/j.jacc.2024.08.061</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453363</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Robert P Frantz</dc:creator>
<dc:creator>Paul M Hassoun</dc:creator>
<dc:creator>Anna R Hemnes</dc:creator>
<dc:creator>Evelyn Horn</dc:creator>
<dc:creator>Jane A Leopold</dc:creator>
<dc:creator>Franz Rischard</dc:creator>
<dc:creator>Erika B Rosenzweig</dc:creator>
<dc:creator>Nicholas S Hill</dc:creator>
<dc:creator>Serpil C Erzurum</dc:creator>
<dc:creator>Gerald J Beck</dc:creator>
<dc:creator>J Emanuel Finet</dc:creator>
<dc:creator>Christine L Jellis</dc:creator>
<dc:creator>Stephen C Mathai</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Implications of Pretest Probability of HFpEF on Outcomes in Precapillary Pulmonary Hypertension</dc:title>
<dc:identifier>pmid:39453363</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.061</dc:identifier>
</item>
<item>
<title>Hemodynamic Insights From Provocative Testing in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453362/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 16:S0735-1097(24)09806-1. doi: 10.1016/j.jacc.2024.09.1226. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453362/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453362</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1226>10.1016/j.jacc.2024.09.1226</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453362</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Isabela Landsteiner</dc:creator>
<dc:creator>Ashvita Ramesh</dc:creator>
<dc:creator>Bin Q Yang</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hemodynamic Insights From Provocative Testing in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39453362</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1226</dc:identifier>
</item>
<item>
<title>Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39453361/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241027181029&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SV-derived AF triggers may have hereditary factors with a favorable postablation prognosis, whereas PA-derived triggers are linked to AF persistence and poor ablation response. Variants near PITX2 may play a pivotal role in extra-PV triggers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 14:S0735-1097(24)08391-8. doi: 10.1016/j.jacc.2024.08.060. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atrial fibrillation (AF) is a prevalent multifactorial arrhythmia associated with specific single-nucleotide polymorphisms (SNPs). Pulmonary vein (PV) isolation is an established treatment for AF; however, recurrence risk remains caused by AF triggers beyond the PVs. Understanding the embryological origins of these triggers could improve treatment outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to investigate the association between embryologically categorized AF triggers, clinical and genetic backgrounds, and postablation prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In cohort 1, comprising 3,067 patients with AF undergoing PV isolation, the clinical characteristics and outcomes were analyzed. Among them, 815 patients underwent genetic analysis using AF-associated SNPs (cohort 2). Patients were delineated based on the developmental origin of the AF triggers: common PV, sinus venosus (SV), and primitive atrium (PA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: SV-origin extra-PV AF triggers occurred in 20.3% (n = 622) of patients, whereas PA-origin triggers occurred in 11.9% (n = 365) of patients in cohort 1. Multivariate analysis of cohort 2 revealed that female sex, lower body mass index, absence of hypertension, rs2634073 near PITX2, and rs6584555 in NEURL1 were associated with SV-AF, whereas nonparoxysmal AF and rs2634073 near PITX2 were predictors of PA-AF. The PA group had a significantly higher arrhythmia recurrence rate after repeated procedures than the common PV (HR: 1.75; 95% CI: 1.34-2.29; P &lt; 0.001) and SV-AF (HR: 1.31; 95% CI: 1.19-1.45; P &lt; 0.001) groups with more de novo AF triggers. However, the incidence of adverse events did not differ significantly among the 3 groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SV-derived AF triggers may have hereditary factors with a favorable postablation prognosis, whereas PA-derived triggers are linked to AF persistence and poor ablation response. Variants near PITX2 may play a pivotal role in extra-PV triggers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39453361/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241027181029&v=2.18.0.post9+e462414">39453361</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.060>10.1016/j.jacc.2024.08.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39453361</guid>
<pubDate>Fri, 25 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Takashi Ikenouchi</dc:creator>
<dc:creator>Junichi Nitta</dc:creator>
<dc:creator>Osamu Inaba</dc:creator>
<dc:creator>Miho Negishi</dc:creator>
<dc:creator>Miki Amemiya</dc:creator>
<dc:creator>Toshikazu Kono</dc:creator>
<dc:creator>Tasuku Yamamoto</dc:creator>
<dc:creator>Kazuya Murata</dc:creator>
<dc:creator>Iwanari Kawamura</dc:creator>
<dc:creator>Kentaro Goto</dc:creator>
<dc:creator>Takuro Nishimura</dc:creator>
<dc:creator>Tomomasa Takamiya</dc:creator>
<dc:creator>Yukihiro Inamura</dc:creator>
<dc:creator>Kensuke Ihara</dc:creator>
<dc:creator>Susumu Tao</dc:creator>
<dc:creator>Akira Sato</dc:creator>
<dc:creator>Masateru Takigawa</dc:creator>
<dc:creator>Yusuke Ebana</dc:creator>
<dc:creator>Shinsuke Miyazaki</dc:creator>
<dc:creator>Tetsuo Sasano</dc:creator>
<dc:creator>Tetsushi Furukawa</dc:creator>
<dc:date>2024-10-25</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Embryological Classification of Arrhythmogenic Triggers Initiating Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39453361</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.060</dc:identifier>
</item>





























</channel>
</rss>